Otros idiomas FSD Pharma Inc.

Acciones

HUGE

CA35954B4047

Mercado cerrado - Canadian Securities Exchange Otros sitios de cotización 21:59:02 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,52 ^CAD	+1,96 %		-21,21 %	-56,67 %

30/04	FSD Pharma Inc. Firma un acuerdo con Applied Science and Performance Institute para llevar a cabo un ensayo clínico en Estados Unidos con el fin de evaluar la seguridad y eficacia de Unbuzzd? en un estado inducido de intoxicación etílica	CI
25/04	FSD Pharma dice que Celly Nutrition se asocia con Six+One para el lanzamiento en EE.UU. de su suplemento dietético	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

FSD Pharma Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd in an Induced State of Alcohol Intoxication	01/05
FSD Pharma : Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy ofunbuzzd™ in an Induced State of Alcohol Intoxication - Form 6-K	30/04
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	30/04
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd	26/04
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	25/04
FSD Pharma Provides another Update on Celly Nu's Anticipated Launch of unbuzzd	23/04
FSD Pharma : Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products - Form 6-K	17/04
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption	16/04
FSD Pharma Receives Nasdaq Non-Compliance Notice	08/04
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	08/04
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
FSD Pharma Signs the Agreement With iNGENu CRO to Conduct a Clinical Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adults	28/03
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	27/03
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	27/03
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	11/03
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	11/03
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 at Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	06/03
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	05/03
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	05/03
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	05/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas FSD Pharma Inc.

Acciones

HUGE

CA35954B4047

Otros idiomas

Filtros